The company sees increased traction in its core segment of studies of evaluating the generic versions of proprietary drugs that go off patent, as well bright prospects from clinical trials of biosimilars and novel drugs.Veeda Clinical Research filing for Rs 500 crore - Rs 700 crore IPO, sources say
The company sees increased traction in its core segment of studies of evaluating the generic versions of proprietary drugs that go off patent, as well bright prospects from clinical trials of biosimilars and novel drugs.
Subscribe to:
Post Comments (Atom)
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
-
The bank plans to raise up to Rs 500 crore by issue of equity shares to qualified institutional buyers through qualified institutional plac...
-
In July, HCL Technologies had announced a Rs 4,000 crore buyback programme for FY19 at a price of Rs 1,100 per equity share.
No comments:
Post a Comment